May 16, 2025

Delandistrogene Moxeparvovec: Efficacy Evidence Questioned

The AAN Guidelines Subcommittee review finds delandistrogene moxeparvovec for DMD failed to meet primary functional outcomes despite FDA approval.

Conexiant

May 16, 2025

CNGB3 Variant Testing Clarifies Genetic Disease Risk

Researchers found that 16 out of 21 CNGB3 gene variants altered RNA splicing, allowing clearer classification of genetic mutations linked to achromatopsia.

Conexiant

May 15, 2025

Assistant Professor Salary Gaps Persist Nationwide

Persistent salary disparities by gender, race, and ethnicity were identified among more than 45,000 U.S. assistant professors, with underrepresented in medicine women learning the least across all specialties.

Conexiant

May 14, 2025

Home Wash Leaves Scrubs Full of Superbugs

Home washing machines often fail to disinfect health care workers' uniforms, leaving antibiotic-resistant bacteria behind.

Conexiant

May 09, 2025

BAL Guides Treatment in Pediatric Respiratory Illness

BAL detected pathogens in 61% of cases and led to treatment changes in nearly 9 out of 10 immunocompromised children with acute respiratory illness, according to a new 5-year study.

Conexiant

May 05, 2025

FDA Monthly Round-up: Key April Updates

April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.

Conexiant

April 30, 2025

FDA Approves FcRn Blocker for Broad gMG Use

The first FcRn blocker for both adult and pediatric generalized myasthenia gravis has been approved by the FDA, based on data showing sustained symptom improvement and IgG reduction in clinical trials.

Conexiant

April 30, 2025

Childhood Wheeze May Be Tied to Ozone Levels

Early-life ozone exposure was linked to increased odds of asthma and wheeze in children aged 4 to 6 years.

Conexiant

April 30, 2025

New Phase III Data on Brensocatib Therapy

Phase III trial results show that once-daily brensocatib reduces pulmonary exacerbations and slows lung function decline in patients with bronchiectasis.

Conexiant